biostudies-literatureUnknown36(1)Meijboom RW<h4>Background</h4>Transitioning patients from an originator to a corresponding biosimilar has been extensively studied in both randomized controlled trials and observational studies. Although transitioning is considered well-tolerated, with no negative impacts on efficacy and/or safety, 2.6-25.8% of patients restart treatment with the originator (retransitioning). Retransitioning to the originator can be considered an indication of biosimilar treatment failure or dissatisfaction with biosimilar treatment. Increasing our knowledge of patients who retransition might help to reduce the number of patients retransitioning.<h4>Objective</h4>Our objective was to estimate the cumulative incidence of patients who retransitioned from a tumor necrosis factor (TNF)-α inhibitor biosimilar to originatoBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy27-39https://www.ebi.ac.uk/biostudies/studies/S-EPMC8847209biostudies-literaturePatients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.PMC8847209Egberts TCGGardarsdottir HGiezen TJMeijboom RWfalsePatients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.<h4>Background</h4>Transitioning patients from an originator to a corresponding biosimilar has been extensively studied in both randomized controlled trials and observational studies. Although transitioning is considered well-tolerated, with no negative impacts on efficacy and/or safety, 2.6-25.8% of patients restart treatment with the originator (retransitioning). Retransitioning to the originator can be considered an indication of biosimilar treatment failure or dissatisfaction with biosimilar treatment. Increasing our knowledge of patients who retransition might help to reduce the number of patients retransitioning.<h4>Objective</h4>Our objective was to estimate the cumulative incidence of patients who retransitioned from a tumor necrosis factor (TNF)-α inhibitor biosimilar to originato2022-01-01T00:00:00Z2022 Jan2025-04-05T11:07:19.75Z2025-04-05T11:07:19.75ZS-EPMC88472093487080210.1007/s40259-021-00508-4